Laboratory Corporation of America Holdings Stock

Equities

LH

US50540R4092

Healthcare Facilities & Services

Market Closed - Nyse 04:00:02 2024-04-25 pm EDT 5-day change 1st Jan Change
198.4 USD -4.61% Intraday chart for Laboratory Corporation of America Holdings -0.55% -12.73%
Sales 2024 * 12.83B Sales 2025 * 13.33B Capitalization 16.72B
Net income 2024 * 1B Net income 2025 * 1.12B EV / Sales 2024 * 1.65 x
Net Debt 2024 * 4.42B Net Debt 2025 * 3.85B EV / Sales 2025 * 1.54 x
P/E ratio 2024 *
16.9 x
P/E ratio 2025 *
15 x
Employees 61,975
Yield 2024 *
1.5%
Yield 2025 *
1.54%
Free-Float 99.66%
More Fundamentals * Assessed data
Dynamic Chart
Evercore ISI Cuts Laboratory Corp of America Holdings' Price Target to $210 From $225 MT
Leerink Partners Adjusts Laboratory Corp of America Price Target to $242 From $260, Keeps Outperform Rating MT
Laboratory Corp of America Q1 Adjusted Earnings, Revenue Increase; 2024 Adjusted EPS Outlook Updated MT
Transcript : Laboratory Corporation of America Holdings, Q1 2024 Earnings Call, Apr 25, 2024
Earnings Flash (LH) LABORATORY CORPORATION OF AMERICA HOLDINGS Reports Q1 Revenue $3.18B, vs. Street Est of $3.12B MT
Earnings Flash (LH) LABORATORY CORPORATION OF AMERICA HOLDINGS Reports Q1 EPS $3.68, vs. Street Est of $3.48 MT
Laboratory Corporation of America Holdings Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Labcorp beats quarterly estimates on strong testing demand RE
North American Morning Briefing : More Tech -2- DJ
Clinical lab operator Labcorp to buy bankrupt genetic test maker Invitae for $239 mln RE
Laboratory Corporation of America Holdings Announces Winning Bid for Select Assets of Invitae CI
Laboratory Corporation of America Holdings (NYSE:LH) won the bid to acquire substantially all of the assets of Invitae Corporation for approximately $240 million. CI
Laboratory Corporation of America Holdings (NYSE:LH) agreed to acquire Substantially all Assets of Invitae Corporation for approximately $240 million. CI
Labcorp Introduces Test for Early Detection of Neurodegenerative Diseases MT
Labcorp Announces First-of-Its-Kind Test for Early Indication of Neurodegenerative Diseases and Brain Injuries Using a Blood Draw CI
More news

Latest transcript on Laboratory Corporation of America Holdings

1 day-4.61%
1 week-0.55%
Current month-9.21%
1 month-7.20%
3 months-12.49%
6 months+0.33%
Current year-12.73%
More quotes
1 week
196.11
Extreme 196.11
210.63
1 month
196.11
Extreme 196.11
218.67
Current year
196.11
Extreme 196.11
234.09
1 year
195.01
Extreme 195.01
243.30
3 years
195.01
Extreme 195.01
317.17
5 years
98.02
Extreme 98.02
317.17
10 years
95.12
Extreme 95.12
317.17
More quotes
Managers TitleAgeSince
Chief Executive Officer 59 13-03-31
Director of Finance/CFO 62 14-06-15
Compliance Officer 65 19-01-31
Members of the board TitleAgeSince
Director/Board Member 75 07-05-15
Chief Executive Officer 59 13-03-31
Director/Board Member 74 95-04-27
More insiders
Date Price Change Volume
24-04-25 198.4 -4.61% 2,098,112
24-04-24 207.9 -0.01% 793,528
24-04-23 208 +2.41% 925,458
24-04-22 203.1 +0.79% 685,960
24-04-19 201.5 +1.02% 768,208

Delayed Quote Nyse, April 25, 2024 at 04:00 pm EDT

More quotes
Laboratory Corporation of America Holdings is the No. 2 clinical laboratory in the United States. Net sales (including intragroup) break down by activity as follows: - clinical laboratory services (63.9%): routine testing, patient diagnosis, disease monitoring and treatment, and other services; - development and clinical trial services (36.1%): for pharmaceutical, biotechnology, medical device and diagnostic companies. Net sales are distributed geographically as follows : North America (81.2%), Europe (12.7%) and other (6.1%).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
198.4 USD
Average target price
241.4 USD
Spread / Average Target
+21.71%
Consensus